U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
Volume -, Issue -, Pages 1-9
Publisher
Cambridge University Press (CUP)
Online
2019-11-28
DOI
10.1017/s0266462319000813
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review
- (2019) Gideon M. Blumenthal et al. Nature Reviews Clinical Oncology
- Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review
- (2019) Sarah Goring et al. BMJ Open
- Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
- (2019) Bishal Gyawali et al. JAMA Internal Medicine
- Real-world Evidence—What Does It Really Mean?
- (2019) Chadi Nabhan et al. JAMA Oncology
- Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies
- (2019) Aviv Ladanie et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- NICE, the NHS, and Cancer Drugs
- (2018) Andrew Dillon et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
- (2018) Alyson Haslam et al. EUROPEAN JOURNAL OF CANCER
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
- (2017) Steven Lemery et al. NEW ENGLAND JOURNAL OF MEDICINE
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- An Important Step Forward for Biosimilars in Cancer Treatment
- (2017) Stephen M. Schleicher et al. JAMA Oncology
- Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines
- (2017) Sebastian Salas-Vega et al. JAMA Oncology
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs
- (2016) Chul Kim et al. MAYO CLINIC PROCEEDINGS
- An appraisal of drug development timelines in the Era of precision oncology
- (2016) Denis Leonardo Jardim et al. Oncotarget
- The Strength of Association Between Surrogate End Points and Survival in Oncology
- (2015) Vinay Prasad et al. JAMA Internal Medicine
- An analysis of FDA-approved drugs for oncology
- (2014) Michael S. Kinch DRUG DISCOVERY TODAY
- A review of economic impact of targeted oral anticancer medications
- (2013) Chan Shen et al. Expert Review of Pharmacoeconomics & Outcomes Research
- The economic pressures for biosimilar drug use in cancer medicine
- (2012) Paul Cornes Targeted Oncology
- Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
- (2011) John R. Johnson et al. JNCI-Journal of the National Cancer Institute
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started